MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial

被引：82

作者：

Chien, A. Jo ^{[1
]}

Tripathy, Debasish ^{[2
]}

Albain, Kathy S. ^{[3
]}

Symmans, W. Fraser ^{[2
]}

Rugo, Hope S. ^{[1
]}

Melisko, Michelle E. ^{[1
]}

Wallace, Anne M. ^{[4
]}

Schwab, Richard ^{[4
]}

Helsten, Teresa ^{[4
]}

Forero-Torres, Andres ^{[5
]}

Stringer-Reasor, Erica ^{[5
]}

Ellis, Erin D. ^{[6
]}

Kaplan, Henry G. ^{[6
]}

Nanda, Rita ^{[7
]}

Jaskowiak, Nora ^{[7
]}

Murthy, Rashmi ^{[2
]}

Godellas, Constantine ^{[3
]}

Boughey, Judy C. ^{[8
]}

Elias, Anthony D. ^{[9
]}

Haley, Barbara B. ^{[10
]}

Kemmer, Kathleen ^{[11
]}

Isaacs, Claudine ^{[12
]}

Clark, Amy S. ^{[13
]}

Lang, Julie E. ^{[14
]}

Lu, Janice ^{[14
]}

Korde, Larissa ^{[15
]}

Edmiston, Kirsten K. ^{[16
]}

Northfelt, Donald W. ^{[17
]}

Viscusi, Rebecca K. ^{[13
,18
]}

Yee, Douglas ^{[19
]}

Perlmutter, Jane ^{[20
]}

Hylton, Nola M. ^{[1
]}

van't Veer, Laura J. ^{[1
]}

DeMichele, Angela

Wilson, Amy ^{[21
]}

Peterson, Garry ^{[1
]}

Buxton, Meredith B. ^{[22
]}

Paoloni, Melissa ^{[22
]}

Clennell, Julia ^{[22
]}

Berry, Scott ^{[22
]}

Matthews, Jeffrey B. ^{[1
]}

Steeg, Katherine ^{[1
]}

Singhrao, Ruby ^{[1
]}

Hirst, Gillian L. ^{[1
]}

Sanil, Ashish ^{[22
]}

Yau, Christina ^{[1
]}

Asare, Smita M. ^{[21
]}

Berry, Donald A. ^{[22
]}

Esserman, Laura J. ^{[1
]}

机构：

[1] Univ Calif San Francisco, 1600 Divisadero St, San Francisco, CA 94115 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Loyola Univ, Chicago, IL 60611 USA

[4] Univ Calif San Diego, La Jolla, CA 92093 USA

[5] Univ Alabama Birmingham, Birmingham, AL USA

[6] Swedish Canc Inst, Seattle, WA USA

[7] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[8] Mayo Clin, Rochester, MN USA

[9] Univ Colorado, Denver, CO 80202 USA

[10] Univ Texas Southwestern, Dallas, TX USA

[11] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[12] Georgetown Univ, Washington, DC USA

[13] Univ Penn, Philadelphia, PA 19104 USA

[14] Univ Southern Calif, Los Angeles, CA 90007 USA

[15] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA

[16] Inova Hlth Syst, Falls Church, VA USA

[17] Mayo Clin, Scottsdale, AZ USA

[18] Univ Arizona, Tucson, AZ USA

[19] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[20] Gemini Grp, Bad Axe, MI USA

[21] Quantum Leap Healthcare Collaborat, San Francisco, CA USA

[22] Berry Consultants, Austin, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 10期

基金：

美国国家卫生研究院;

关键词：

PATHOLOGICAL COMPLETE RESPONSE; AKT-INHIBITOR MK-2206; DOUBLE-BLIND; ADAPTIVE RANDOMIZATION; PIK3CA MUTATIONS; PLUS PACLITAXEL; TRASTUZUMAB; EVEROLIMUS; MULTICENTER; COMBINATION;

D O I：

10.1200/JCO.19.01027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThe phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer.PATIENTS AND METHODSI-SPY 2 is a multicenter, phase II, open-label, adaptively randomized neoadjuvant platform trial that screens experimental therapies and efficiently identifies potential predictive biomarker signatures. Patients are categorized by human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), and MammaPrint statuses in a 2 x 2 x 2 layout. Patients within each of these 8 biomarker subtypes are adaptively randomly assigned to one of several experimental therapies, including MK-2206, or control. Therapies are evaluated for 10 biomarker signatures, each of which is a combination of these subtypes. The primary end point is pathologic complete response (pCR). A therapy graduates with one or more of these signatures if and when it has an 85% Bayesian predictive probability of success in a hypothetical phase III trial, adjusting for biomarker covariates. Patients in the current report received standard taxane- and anthracycline-based neoadjuvant therapy without (control) or with oral MK-2206 135 mg/week.RESULTSMK-2206 graduated with 94 patients and 57 concurrently randomly assigned controls in 3 graduation signatures: HR-negative/HER2-positive, HR-negative, and HER2-positive. Respective Bayesian mean covariate-adjusted pCR rates and percentage probability that MK-2206 is superior to control were 0.48:0.29 (97%), 0.62:0.36 (99%), and 0.46:0.26 (94%). In exploratory analyses, MK-2206 evinced a numerical improvement in event-free survival in its graduating signatures. The most significant grade 3-4 toxicity was rash (14% maculopapular, 8.6% acneiform).CONCLUSIONThe Akt inhibitor MK-2206 combined with standard neoadjuvant therapy resulted in higher estimated pCR rates in HR-negative and HER2-positive breast cancer. Although MK-2206 is not being further developed at this time, this class of agents remains of clinical interest. (c) 2020 by American Society of Clinical Oncology

引用

页码：1059 / +

页数：13

共 50 条

[1] Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer
Xu, Junnan
Bao, Hua
Wu, Xue
Wang, Xiaonan
Shao, Yang W.
Sun, Tao
ONCOLOGY LETTERS, 2019, 18 (01) : 449 - 455
[2] Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.
Tripathy, Debu
Chien, Amy Jo
Hylton, Nola
Buxton, Meredith Becker
Ewing, Cheryl Ann
Wallace, Anne M.
Forero, Andres
Kaplan, Henry G.
Nanda, Rita
Albain, Kathy S.
Moulder, Stacy L.
Haley, Barbara B.
DeMichele, Angela
Symmans, William Fraser
van't Veer, Laura
Paoloni, Melissa
Esserman, Laura
Berry, Donald A.
Yee, Douglas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[3] Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients
Mazzarella, Luca
Disalvatore, Davide
Bagnardi, Vincenzo
Rotmensz, Nicole
Galbiati, Donata
Caputo, Sara
Curigliano, Giuseppe
Pelicci, Pier Giuseppe
EUROPEAN JOURNAL OF CANCER, 2013, 49 (17) : 3588 - 3597
[4] Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Denkert, Carsten
von Minckwitz, Gunter
Brase, Jan C.
Sinn, Bruno V.
Gade, Stephan
Kronenwett, Ralf
Pfitzner, Berit M.
Salat, Christoph
Loi, Sherene
Schmitt, Wolfgang D.
Schem, Christian
Fisch, Karin
Darb-Esfahani, Silvia
Mehta, Keyur
Sotiriou, Christos
Wienert, Stephan
Klare, Peter
Andre, Fabrice
Klauschen, Frederick
Blohmer, Jens-Uwe
Krappmann, Kristin
Schmidt, Marcus
Tesch, Hans
Kuemmel, Sherko
Sinn, Peter
Jackisch, Christian
Dietel, Manfred
Reimer, Toralf
Untch, Michael
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 983 - 991
[5] Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Wolff, Antonio C.
Tung, Nadine M.
Carey, Lisa A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2189 - +
[6] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
Naoki Hayashi
Naoki Niikura
Hideko Yamauchi
Seigo Nakamura
Naoto T. Ueno
Breast Cancer Research and Treatment, 2013, 137 : 523 - 531
[7] Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
Hayashi, Naoki
Niikura, Naoki
Yamauchi, Hideko
Nakamura, Seigo
Ueno, Naoto T.
BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 523 - 531
[8] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
Kemp, Zoe
Jones, Alison
ADVANCES IN THERAPY, 2011, 28 (08) : 603 - 614
[9] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
Zoe Kemp
Alison Jones
Advances in Therapy, 2011, 28 : 603 - 614
[10] Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Wolf, Denise
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Schmidt, Emmett
Townson, Steven
Cristescu, Razvan
Asare, Smita
Berry, Don
Esserman, Laura
van't Veer, Laura
Tripathy, Debu
Chien, Jo
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →